FULC

FULC

USD

Fulcrum Therapeutics Inc. Common Stock

$8.370-0.460 (-5.210%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$8.830

最高

$9.020

最低

$8.300

交易量

0.37M

公司基本面

市值

453.0M

行業

生物科技

國家

United States

交易統計

平均交易量

0.53M

交易所

NGM

貨幣

USD

52週範圍

最低 $2.315當前 $8.370最高 $10.11

相關新聞

GlobeNewswire

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be

查看更多
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Analyst Upgrades

RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7

RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics with a Sector Perform and raises the price target from $5 to $7.

查看更多
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7
Analyst Upgrades

Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16

Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics with a Overweight and raises the price target from $12.5 to $16.

查看更多
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16
GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the

查看更多
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
GlobeNewswire

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives

查看更多
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET